A b s t r a c t Introduction: Liquid-based cytology allows to apply modern and specific analyses of hrHPV genotyping in p16/Ki-67 test. All of these together could raise accuracy ratio for high-grade squamous intraepithelial lesion above 90%. The purpose of this study was to evaluate the diagnostic accuracy of LBC, hrHPV testing, and p16/Ki-67 testing in diagnosis of high-grade cervical intraepithelial lesions. Material and methods: The study consisted of 176 women, out of which 50 presented with HSIL (CIN2) SCC (cervical intraepithelial lesion grade 2 squamous cell carcinoma). 126 women with a negative Pap test were pooled into the second group of the study. All patients were resampled for LBC, HPV genotyping, and for the p16/Ki-67 test. The research was carried out between May and December 2017, and second sampling were taken from 1 to 4 months. Results: We reported a strong correlation between positive Pap test and hrHPV (p < 0.05) that met accuracy close to 90%. We noted correlations between a positive p16/Ki-67 with a positive Pap test: p < 0.001; 66% sensitivity (95% CI: 51.2-78.8%), 87.8% specificity (95% CI: 75.2-95.4%), 76.8% accuracy (95% CI: 67.2-84.7%), and OR 13.9 (95% CI: 4.9-39.2), especially HSIL and HPV16: p < 0.001; sensitivity (95% CI) 64.0, specificity (95% CI) 98.4, accuracy (95% CI) 88.6, OR (95% CI) 109.3.
Introduction
Over 500,000 new cases of cervical cancer are reported worldwide each year, with about 27,000 fatal outcomes [1] . However, a recent meta-analysis restricted to the population of China illustrates the clinical aspect of cervical cancer treatment strategy, and although an additional innovative pelvic hyperthermia was applied, the 3-year survival rate remained unchanged (OR = 1.17) [2] . In order to decrease cervical cancer incidence ratio, the screening programs have been undergoing modification for the last years. National guidelines determine the type of program, terminology, monitoring, and quality control. The implementation of such a program must fulfil many conditions such as design, planning, feasibility testing, piloting and trial launching, scaling up health service delivery, running of full-scale programme, and finally sustainability [3] . In 1988, during a meeting of the National Institutes of Health in Bethesda, Maryland, USA, a new system for reporting cervical cytology was introduced and approved -the Bethesda system (TBS), which is still a fundamental algorithm for patients' management on daily basis. In 2001 and most recently in 2014, TBS was modified, and 'undetermined significance' category and liquid-based cytology (LBC) principles were introduced [4] [5] [6] . In clinical practice, the introduction of the ASC-US, ASC-H ('atypical squamous cells cannot exclude HSIL'), and LSIL categories significantly increased the number of ambiguous results of Pap smears that needed further verification, which in turn greatly increased the cost of screening but also led to improve high-grade detection ratio [7] . At that time, the American Society for Colposcopy and Cervical Pathology (ASCCP) has accepted the strategy for clinical treatment according to the TBS [8] . This was the first time when reporting terminology was correlated with HPV biology and clinical management. The recent cutting-edge solutions like LBC, computer-assisted imaging, and HPV-testing have been implemented over the past decade; however, looking from time perspective, only hrHPV testing significantly improved the HSIL detection ratio [9] [10] [11] [12] . The LBC has significantly decreased the ratio of inadequate smears, improved the detection of low-grade squamous intraepithelial lesion (LSIL) and ASC-US, and increased the number of colposcopy and recent intraepithelial neoplasia diagnosis. Moreover, this allowed to keep a high detection rate of HSIL, irrespectively of patient age [13] [14] [15] . Recently, the molecular status of hrHPV, especially HPV type 16 or 18 testing and prophylactic HPV vaccines, have been added to cervical cancer screening program and management guidelines. Liquid-based cytology is a technique, which has taken over conventional cytology (CC) in some countries. In Europe, Denmark and the Netherlands have implemented LBC-based screening as first [13] [14] [15] [16] . Technically, LBC assay takes about 50% of sample volume to prepare slides, and the remaining sample, stored in the vial as a cell suspension, can be used for immunocytochemistry, molecular testing of infectious agents, DNA cytometry, and DNA ploidy analysis.
The p16/Ki-67 test provides an insight to HPV E6 and E7 oncoproteins underlying molecular disturbances. They inhibit the suppressor genes p53 and Rb leading to their inactivation, respectively. In effect, the connection between E7 and Rb gene promotes cell proliferation that could be visualized by cytoplasmic p16 overload and Ki-67 protein accumulation in nuclear compartment. The p16/Ki-67 and hrHPV-positive tests greatly correlate with high-grade cervical intraepithelial lesion, reaching accuracy ratio over 90% [11, 17, 18] .
This way of screening could be much more efficient than CC assuming that the specificity and sensitivity ratio of LBC and hrHPV co-tests stands for over 90%. Recently ended the ATHENA trial covering above 42,000 U.S. women ≥ 25 years compared sensitivity/ specificity of Pap cytology (ThinPrep © ), hybrid strategy (cytology and HPV test), and HPV as primary screening. Conclusions pointed hrHPV testing as the most well-balanced and efficient [9, 10] .
To reach high detection rate of HSIL, in many papers, a lot of effort has been devoted to quality control and reproducibility of molecular solutions used for HPV typing. Conclusions were mostly similar: keeping full validation from the stage of sampling through storage, adequate equipment, and analysis are crucial [19] [20] [21] [22] . However, the relatively high-cost of testing (roughly 40 USD per singular DNA-HPV or singular p16/Ki-67 test) was pointed out and a national screening provider should face new reality by employing such modern techniques.
The aim of this study was to evaluate the diagnostic accuracy and value of LBC, hrHPV testing, and dual-stained p16/Ki-67 test in the diagnosis of high-grade cervical intraepithelial lesions including cervical cancer.
Material and methods
This regional, Polish multicenter prospective study included patients from the Clinic of Gynecology and Obstetrics, Complex Voivodship Hospital and the Department of Gynecology, HollyCross Oncology Centre in Kielce who had a CC performed. All enrolled patients were divided into two groups. The including criteria for group 1 were as follows: negative CC, negative previous screening history, and negative gynecological examination including colposcopy. Group 2 consisted of women with positive CC with cytological report covering ASUS-US, ASC-H, LSIL, HSIL, and SCC. As inclusion criteria included high-grade cervical neoplasia (HSIL) confirmed by cervical biopsy as spectrum lesion ranging from CIN2 to SCC, the time from CC to second sampling was from 1 to 4 months and no treatment to date. Patients who did not fulfilled the criteria were excluded.
All enrolled patients were reinvited for additional sampling for LBC, hrHPV molecular test, and p16/Ki-67 test. The research was carried out between May 2017 and December 2017, and a written consent was obtained from all participants.
The LBC were performed in the Pathology Department of Jan Kochanowski, University in Kielce using the LBC SurePath TM system. Cytological findings were categorized according to the updated 2014 TBS protocol [6] ). All employed solutions met the criteria of CE IVD (EU directive for the 'in-vitro-diagnostic medical devices') and FDA (the Food and Drug Agency), and are used in many national screening programs worldwide. SurePath © LBC and hrHPV Cobas © tests were performed in every case. One patient was excluded from the study due to an invalid PCR test.
LBC and p16/Ki-67 immunocytochemical reactions were analyzed by three independent pathologists (PL, MK, AN-G) blinded to the clinical data. All observed data was tabulated and then statistically analyzed. All inter-observer discrepancies were collectively reanalyzed and to final calculations consensus results were used.
Statistical analysis
Categorical data was expressed as number and percentage. Chi-square (c 2 ) test or Fisher's exact test were applied to compare proportions. Numerical variables were presented as median and interquartile range and compared by Mann-Whitney U test. Interobserver variabilities were assessed by Cohen's k coefficient. Sensitivity, specificity, accuracy, and odds ratio (OR) with 95% confidence intervals (95% CI) were also calculated. A two tailed p-value < 0.05 was considered as statistically significant. All statistical analyses were performed using R (version 3.1.2; the R Foundation for Statistical Computing, Vienna, Austria) or Statistica (StatSoft, Inc., 2014, version 12).
Results
One hundred and seventy five women ranging from 21 to 67 years of age (average age: 37.5; STD, 10.4; median, 34) were included in the analysis. Group 1 consisted of 126 women, age ranging from 21 to 67 (average: 38.3 years). Group 2 included 50 patients, with age ranging from 23 to 59 (average: 35.3 years). There were no statistical differences between the groups according to age (p = 0.14). Applied solution resulted in 0.5% ratio of unsatisfactory slides and 8% HSIL underdiagnosis by CC versus LBC. Blinded to clinical data pathologists reached 62% specificity to detect HSIL. The remaining 19 patients were coded as non-HSIL spectrum lesions. Table III) .
The positive Pap test, confirmed by biopsy as CIN2-SCC, could be the golden standard to esti-mate HSIL detection. Our data concerning p16/Ki-67 test efficiency was as follows: 66% sensitivity (95% CI: 51.2-78.8%), 87.8% specificity (95% CI: 75.2-95.4%), 76.8% accuracy (95% CI: 67.2-84.7%), and OR = 13.9 (95% CI: 4.9-39.2). The highest percentage of positive p16/Ki-67 tests was observed in patients with positive cytology and positive hrHPV (p < 0.001) (Figure 1 ).
Discussion
The past decade has been fruitful in attempts to improve cervical cancer screening productivity.
It seems that CC has been irretrievably replaced by much more efficient LBC and additional molecular and immunological tests.
In our SurePath study, we met 0.5% unsatisfactory slides and 8% HSIL under-diagnosis by CC versus LBC. The Dutch study by Rozemeijer et al. published a large-cohort studies demonstrating the advantage of LBC over CC. The authors compared the sensitivity of CC, SurePath, and ThinPrep methods. They observed a 14% improvement in the detection of CIN I and CIN II using SurePath vs. CC. ThinPrep did not improve the CIN detection rate. In more recent study, HR at 0.81 was associ- ated with a 19% lower risk of cervical cancer using SurePath vs. CC. This large cohort study covered most parts of The Netherlands, and we reached a similar value of specificity at slightly above 60% [13, 14] . Similarly, Beerman et al. reported higher detection of ASC-US+ (2.97% vs. 1.64%, p < 0.001) and a lower rate of unsatisfactory slides with SurePath compared to CC (0.13% vs. 0.89%, p < 0.001) [15] . In light of our observation, high-grade lesions were masked by ASC-US or ASC-H, which proves missing many HSIL using CC only. Table II shows a 42% ratio of HSIL underdiagnosis by LBC and instead of HSIL, the LSIL, ASC-US, and ASC-H were diagnosed. We noted a strong correlation between HPV16 and 'HPV other' with positive cytological findings. Furthermore, a positive p16/Ki-67 test strongly correlated with HPV16, particularly with HSIL (p < 00001). These results confirm the crucial 
